<DOC>
	<DOCNO>NCT01627314</DOCNO>
	<brief_summary>This study open-label randomize , prospectively historically control trial safety efficacy single ProHema-CB unit use part double CB transplant follow myeloablative reduce intensity conditioning subject age 15-65 year hematologic malignancy . A maximum 60 eligible subject enrol treated trial approximately 10 center within U.S .</brief_summary>
	<brief_title>The PUMA Trial Trial Single ProHema Modulated-CB Unit Part Double CB Transplant Patients With Hematologic Malignancies .</brief_title>
	<detailed_description>All subject receive myeloablative reduce intensity condition regimen , receive 2 HLA-matched UCB unit . A total 40 subject receive one ProHema-CB part double CB transplant additional 20 subject enrol concurrent control . The determination CB unit ProHema-CB unit make base primarily upon degree HLA match .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Subjects hematologic malignancy allogeneic stem cell transplantation deem clinically appropriate . Eligible disease stage include : Acute lymphoblastic leukemia ( include T lymphoblastic leukemia ) complete remission . Remission define &lt; 5 % blast morphological characteristic acute leukemia bone marrow &gt; 20 % cellularity . Acute myelogenous leukemia high risk first CR second subsequent CR . High risk first CR define limit least one follow factor : great 1 cycle induction chemotherapy achieve CR , prior myelodysplastic syndrome ( MDS ) , presence Flt3 abnormality , FAB M6 M7 subtypes leukemia , adverse cytogenetics . Remission define &lt; 5 % blast morphological characteristic acute leukemia ( e.g . Auer Rods ) bone marrow &gt; 20 % cellularity . Biphenotypic/Undifferentiated leukemia first subsequent CR ( definition CR ALL/AML ) . NonHodgkin 's lymphoma ( Tcell , large cell mantle cell ) Hodgkin 's lymphoma second subsequent complete remission ( CR ) partial remission ( PR ) document chemosensitivity . In addition , marginal zone lymphoma follicular lymphoma progress ≥ 2 therapy ( exclude singleagent rituximab ) . No history prior myeloablative procedure . 2 . Lack suitable 56/6 HLAmatched related ( institutional guideline dictate ) suitable 8/8 HLAA , B , C , DRß1 match unrelated donor ; unrelated donor available within appropriate timeframe . 3 . Age 1565 year . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 5 . Signed IRB approve Informed Consent Form ( ICF ) . 1 . History prior allogeneic transplantation 2 . Cardiac disease : symptomatic congestive heart failure evidence leave ventricular dysfunction ( Ejection fraction &lt; 40 % ) measure gated radionuclide ventriculogram echocardiogram ; active angina pectoris , uncontrolled hypertension ; history myocardial infarction depress ejection fraction . 3 . Pulmonary disease : symptomatic chronic obstructive lung disease , symptomatic restrictive lung disease , correct DLCO &lt; 50 % predict , correct hemoglobin . 4 . Renal disease : serum creatinine &gt; 2.0 mg/dl calculate creatinine clearance &lt; 40 mL/min . 5 . Hepatic disease : serum bilirubin &gt; 2.0 mg/dl ( except case Gilbert 's syndrome ongoing hemolytic anemia ) , SGOT SGPT &gt; 5 x upper limit normal . 6 . Neurologic disease : symptomatic leukoencephalopathy , active CNS malignancy neuropsychiatric abnormality believe preclude transplantation . 7 . HIV antibody . 8 . Uncontrolled infection . 9 . Pregnancy breast feed mother . 10 . Inability comply requirement care allogeneic stem cell transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>